BioTelemetry, Inc. Announces Its Latest Success in Patent Enforcement
July 20 2016 - 8:45AM
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care, is pleased to
announce that the District Court in the District of
Massachusetts has entered a July 14, 2016 Consent
Judgment permanently enjoining and
restraining InfoBionic, Inc. (“InfoBionic”) from “making,
using, offering to sell, or selling within the United
States or importing into the United States” any of
its “First-Generation” MoMe® Kardia system and
from “engaging in any other act of infringement” by its
“First-Generation” system as defined under
federal patent law.
BioTelemetry is pleased with this initial
result, and has pending patent infringement claims
against InfoBionic’s “Second-Generation” MoMe® Kardia
system as well as claims for misappropriation
of BioTelemetry’s trade secrets. BioTelemetry has
asserted that such trade secrets were misappropriated, in
part, by one or more former
BioTelemetry executives and
employees who joined InfoBionic and were
involved in the development of its MoMe® Kardia
system.
BioTelemetry is represented by a litigation team from Sidley
Austin LLP’s New York office.
About BioTelemetry
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the
leading wireless medical technology company focused on the delivery
of health information to improve quality of life and reduce cost of
care. The company currently provides cardiac monitoring
services, original equipment manufacturing with a primary focus on
cardiac monitoring devices and centralized cardiac core laboratory
services. More information can be found at
www.biotelinc.com.
Cautionary Statement Regarding Forward-Looking
Statements
This document includes certain forward-looking statements within
the meaning of the "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as "expect," "anticipate," "estimate,"
"intend," "plan," "believe," "promises" and other words and terms
of similar meaning. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any
of these expectations, and could cause actual outcomes and results
to differ materially from current expectations. These factors
include, among other things, our ability to defend our patent
portfolio and obtain favorable results, effects of changes in
health care legislation, effectiveness of our cost savings
initiatives, relationships with our government and commercial
payors, changes to insurance coverage and reimbursement levels for
our products, the success of our sales and marketing initiatives,
our ability to attract and retain talented executive management and
sales personnel, our ability to identify acquisition candidates,
acquire them on attractive terms and integrate their operations
into our business, the commercialization of new products, market
factors, internal research and development initiatives, partnered
research and development initiatives, competitive product
development, changes in governmental regulations and legislation,
the continued consolidation of payors, acceptance of our new
products and services, patent protection, adverse regulatory
action, litigation success, our ability to successfully create a
new holding company structure and to anticipate the benefits of
such structure. For further details and a discussion of these and
other risks and uncertainties, please see our public filings with
the Securities and Exchange Commission, including our latest
periodic reports on Form 10-K and 10-Q. We undertake no obligation
to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.
Contact:
BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
investorrelations@biotelinc.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024